ClinicalTrials.gg
Sign In
RecruitingNCT05714449Updated Oct 8, 2026

OCT Eccentric Fixation and Amblyopia in Children

An interventional study of eye patch and After-image and MIT trainer in Amblyopia, sponsored by State University of New York College of Optometry. Recruiting at 1 site in United States. Open to participants aged 4 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by State University of New York College of Optometry · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 9 months later.
Updated Oct 8, 2026Primary completion movedStudy completion movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
4 Years to 16 Years
Sex
All
01

Study summary

The objectives of this proposal are to characterize the relationship between OCT eccentric fixation (OCT-EF), fixation eye movement (FEM), macular sensitivity in children with amblyopia.

Read the detailed description

Aim 1. OCT EF changes with patching treatment at 12 weeks visit.

Aim 2. OCT EF changes with foveation therapy.

02

Conditions studied

  • Amblyopia

Browse trials for

Keywords

  • eccentric fixation
  • amblyopia
  • patching
  • foveation therapy
  • OCT
03

In context

Amblyopia

189 studies on the registry are indexed under Amblyopia; 41 are open to participants now.

This study's planned enrollment of 30 is below the median of 60 across 137 interventional studies indexed under Amblyopia.

Browse Amblyopia studies →

Lead sponsor

State University of New York College of Optometry is the lead sponsor of 17 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. children with best-corrected visual acuity (BCVA) of 20/40 (equivalent to 0.3 logMAR) or worse in the amblyopic eye (ranging from 20/40 to 20/400), and interocular difference of BCVA was at least two logMAR lines,

  2. ocular causes of amblyopia that were identified as refractive(i.e., anisometropic, strabismus, or strabismic-anisometropic.

    • Anisometropia included interocular difference of spherical equivalent >=1D or interocular difference of astigmatism cylinder magnitude >=1D;
    • strabismus included those with deviation >=10PD or good alignment after prior strabismus surgery;
    • combined type included those who meet the criteria of both anisometropia and strabismus.
    • For the patching group, we will enroll 15 children with strabismic amblyopia who are prescribed patching treatment. Age: 4-12 years old.
    • For the foveation therapy group, we will enroll 15 children with strabismic amblyopia who are prescribed foveation therapies. Age: 8-16 years old.

Exclusion criteria

Exclusion Criteria:

  • born before 32 weeks gestational age;
  • neurologic, developmental, or systemic illnesses known to be associated with ocular pathologies;
  • congenital or acquired macular pathology.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Patching group

    part-time patching following PEDIG guidelines.

    Device: eye patch

  • Experimental
    foveation therapy

    After-image foveation therapy training is 10 mins; MIT training is 5 minutes.

    Device: After-image and MIT trainer

Interventions

  • Deviceeye patch

    standard amblyopia treatment

  • DeviceAfter-image and MIT trainer

    Common clinical training for foveation

06

What researchers measure

Primary outcomes

  1. OCT eccentric fixation

    eccentric fixation measured with OCT imaging.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Feb 2027, 48 months after the start.

Of 58 non-industry interventional studies with no phase under Amblyopia, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 72. This study's planned 48 months is above that.

Counting every sponsor, half of 71 studies reached it within 33 months; a quarter within 17 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Jan 2025 → Feb 2027 and completion Jan 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2023
First posted
Feb 6, 2023
StartActual
Jan 25, 2023
Primary completionEst.
Feb 24, 2027was Jan 2025
CompletionEst.
Mar 24, 2027was Jan 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 24, 2025→Feb 24, 2027
Oct 8, 2026
Study completion
Jan 24, 2026→Mar 24, 2027
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Primary completion Jan 24, 2025→Feb 24, 2027
    Study completion Jan 24, 2026→Mar 24, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05714449
Lead sponsor
State University of New York College of Optometry
Responsible party
Jingyun Wang (Associate Professor, State University of New York College of Optometry) — Principal investigator
First posted
Feb 6, 2023
Start date
Jan 25, 2023
Primary completion
Feb 24, 2027 (estimated)
Completion
Mar 24, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Jingyun Wang, PhD
Contact
jwang@sunyopt.edu
2129385759
Jingyun Wang
principal investigator · SUNY College of Optmetry

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Amblyopia →

Other studies from this sponsor

State University of New York College of Optometry

Start the discussion